Shi-Qi Wu

Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer.

Yi Zou, R. Cao, Yun-Gen Xu, 2022, European journal of medicinal chemistry.

Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.

Qihua Zhu, Yi Zou, Yun-Gen Xu, 2021, Journal of medicinal chemistry.

FDI-6 and Olaparib Synergistically Inhibit the Growth of Pancreatic Cancer by Repressing BUB1, BRCA1 and CDC25A Signaling Pathways.

Yun-Gen Xu, Shu-Ping Wang, Shih-Hui Huang, 2021, Pharmacological research.

FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair

Yun-Gen Xu, Shu-Ping Wang, Feng Liu, 2021, Cell Death & Disease.

Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy

Qihua Zhu, Jinjin Sun, Yungen Xu, 2020, Molecules.

Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy.

Xi Xu, Jinlei Bian, Zekun Du, 2023, European journal of medicinal chemistry.